[New antithrombotic drugs: fondaparinux, idraparinux, ximelagatran].
Antithrombotic drugs: heparins and oral vitamin K antimetabolites are connected with many side effects, which delimit their application in clinical practise. Continuous research has led to synthesis of new drugs which are safer and easier in use. Actually used antithrombotic drugs with their faults are discussed. Mechanism of action and data from trials relating to efficacy and safety of new drugs: fondaparinux, idraparinux and ximelagatran are presented.
Rewiuk
Krzysztof
K
Katedra Chorób Wewnetrznych i Gerontologii Collegium Medicum Uniwersytetu Jagiellońskiego. rewiuk@mp.pl
Franczuk
Paweł
P
Grodzicki
Tomasz
T
D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines / Q000009:adverse effects / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077425:Fondaparinux; D006801:Humans; D009844:Oligosaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control*
D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; D011134:Polysaccharides; C426686:ximelagatran; C479958:idraparinux; D000077425:Fondaparinux